Abstract
We aimed to characterize the variability in the illness experience and recovery process from COVID-19. We conducted in-depth individual interviews with participants enrolled in the Long-term Immunological Impact of Novel Coronavirus (LIINC) cohort study in San Francisco, California from June through October of 2020. Participants were adults who had a previously confirmed positive SARV-CoV-2 nucleic acid amplification test result, had recovered or were recovering from acute infection, and underwent serial evaluations at our clinical research center. We purposefully sampled 24 English- and Spanish-speaking adults with asymptomatic, mild and severe symptomatic infection, including those who were hospitalized, and those with HIV co-infection. Half of our sample (50.0%) identified as Latinx/Hispanic and most of the participants were men (62.5%). We used thematic analysis to characterize the illness experience, recovery process, and mental health impact of experiencing COVID-19 and present clinical data for each participant. Emergent themes were: (1) across symptom profiles and severity, experiencing COVID-19 was associated with psychological distress, (2) among participants with symptomatic infection, the illness experience was characterized by uncertainty in terms of managing symptoms and recovery, and (3) despite wide-ranging illness experiences, participants shared many common characteristics, including health information-seeking behavior facilitated by access to medical care, and uncertainty regarding the course of their illness and recovery. COVID-19 was associated with elevated levels of psychological distress, regardless of symptoms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute of Allergy and Infectious Diseases NIH/NIAID 3R01AI141003-03S1 [to TJH], NIH/NIAID R01AI158013 [to MG and MS] and by the San Francisco General Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine. MJP is supported on NIH T32 AI60530-12 and by the UCSF Resource Allocation Program. JDK is supported on NIH/NIAID AI135037. EIS was supported by NIH-NIMH T32 MH019105. AM and part of this work was assisted by the UCSF-Gladstone Center for AIDS Research NIH P30AI027763.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board at the University of California, San Francisco.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by the National Institute of Allergy and Infectious Diseases NIH/NIAID 3R01AI141003-03S1 [to TJH], NIH/NIAID R01AI158013 [to MG and MS] and by the San Francisco General Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine. MJP is supported on NIH T32 AI60530-12 and by the UCSF Resource Allocation Program. JDK is supported on NIH/NIAID AI135037. EIS was supported by NIH-NIMH T32 MH019105. AM and part of this work was assisted by the UCSF-Gladstone Center for AIDS Research NIH P30AI027763.
An erratum in a key term was updated in this paper.
Data Availability
The data are available with a formal request to the principal investigative team and with a data sharing plan to protect against breaches of confidentiality.
